Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus

Documenti analoghi

• Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity
  di: Naïm Bouazza, et al.
  Pubblicazione: (2025)
• Model‐based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer
  di: Yue Zhao, et al.
  Pubblicazione: (2024)
• Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study
  di: Xiaoying Zhao, et al.
  Pubblicazione: (2025)
• Population pharmacokinetics and exposure–response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY
  di: Mita Kuchimanchi, et al.
  Pubblicazione: (2024)
• Population pharmacokinetics of levofloxacin in breastmilk in patients with rifampicin‐resistant tuberculosis
  di: Sharon Sawe, et al.
  Pubblicazione: (2025)